1
00:00:00,000 --> 00:00:06,667
Vasoactive intestinal peptide, or VIP, has attracted interest for its biological effects in the lungs.

2
00:00:06,667 --> 00:00:10,917
Aviptadil is the synthetic VIP studied in clinical research.

3
00:00:10,917 --> 00:00:16,792
The TESICO randomized trial tested intravenous aviptadil in people hospitalized with severe COVID-19

4
00:00:16,792 --> 00:00:21,875
respiratory failure. Its primary outcome assessed recovery status through day 90.

5
00:00:21,875 --> 00:00:26,542
Aviptadil did not significantly improve that outcome compared with placebo.

6
00:00:26,542 --> 00:00:33,208
The trial was stopped for futility. Low blood pressure, flushing, and diarrhea were important safety

7
00:00:33,208 --> 00:00:36,708
observations.

8
00:00:36,708 --> 00:00:41,375
This result applies to the tested illness, route, and setting.

9
00:00:41,375 --> 00:00:47,250
It illustrates why laboratory mechanisms need clinical testing, without settling every research question

10
00:00:47,250 --> 00:00:50,750
about VIP.